The high-affinity receptor for IgG, Fc-yRI, expressed on monocytes and interferon-7 (IFN-7)-stimulated neutrophils, is a trigger molecule for cell-mediated cytotoxicity. We 
INTRODUCTION

Although
MURiNE monoclonal antibodies (MoAb) directed to tumor-associated antigens have considerable therapeutic potential, there are also several limitations to their use in vivo (Dillman, 1989) . These include lack of host cellular or humoral effector mechanisms, immune response to the foreign protein, and delivery of adequate amounts of the MoAb to the tumor. For a MoAb to be an effective anticancer agent, it is necessary that it work in concert with an effector mechanism such as complement (Stepan et al, 1984) or a cellular effector, as in antibody-dependent cellular cytotoxicity (ADCC)' (Ortaldo et al, 1987) . Many potentially useful MoAbs are not able to use these effector mechanisms because they are not of the appropriate subclass of immunoglobulin. It has become clear that murine Ig of the IgG2a and IgG3 subclasses are the most effective at mediating ADCC by virtue of their ability to bind to the high-affinity Fc receptor, FC7RI (Lübeck et al, 1985) . Murine (Steplewski et al, 1988) .
In this paper, we describe an approach to overcoming some of the limitations of certain MoAbs for in vivo therapy. We have prepared murine MoAbs (MoAb 22 and MoAb 32) that bind to FC7RI outside the ligand binding site, and thus their ability to bind to and trigger cytotoxicity through this receptor is not competed by other immunoglobulins. Bispecific antibodies (BsAbs) were previously shown to mediate ADCC of red blood cells that was not inhibited by nonimmune human IgG (Shen et al, 1986a (Ball et al, 1983) . SKBR-3 cells (ATCC) were cultured in DMEM + 10% FBS. Monocytes were purified as previously described (Shen et al, 1986b) . Briefly, mononuclear cells were harvested from the peripheral blood of normal donors by leukapheresis. The monocytes were further purified by separation over Histopaque (Sigma Chemical Co., St. Louis, MO), and incubation with rotation at 4°C (Shen et al, 1986b) . The resulting aggregates were allowed to sediment and then sedimented again through FBS. The resulting preparations were >95% monocytes as assessed by morphological examination of Wright's-Giemsa-stained cytospins and expression of CD14.
The hybridomas PM81 (Bell etal, 1983) , 32 (Anderson et al, 1986) , and 22 (Guyre era/, 1989) were tested for mycoplasma, sterility, and murine viruses by the MAP test and found to be free of contamination. The hybridomas were cultured in MF-1 medium (modified Excell-300, J.R. Scientific) containing 0.5% FBS.
Production of MoAbs
Antibodies were produced using hollow-fiber technology, with a serum-free, low-protein media feed stream. Each MoAb was purified from harvests of antibody-rich supernatant from a hollow-fiber cartridge using high-performance liquid chromatography (HPLC) 
RESULTS
Characteristics of BsAb
The ability of the BsAb to bind to antigen-positive target cells was assessed by flow cytometry. As shown in Fig. 1 BsAb. This assay indicated that maximal attachment of the CD64+ U937 cells to the CD15+ SKBR-3 cells occurred at 5 p,g/ml of BsAb and that both the PM81 x 32andthePM81 x 22 BsAbs were similarly effective in mediating conjugate formation between these cells (Fig. 2) (Fig. 3) . Using the chromium release assay and correcting for background lysis, 30-35% killing was demonstrated using 0.5-1.0 |xg/ml of BsAb, with lesser killing at both higher and lower concentrations. Monospecific PM81 had little activity in this assay in the absence of serum, and combining two bispecifics made from the same tumor-specific MoAb did not significantly increase cytotoxicity. Thus, these BsAbs mediate ADCC of HL-60 target cells whereas PM81 alone does not. However, in the presence of fresh human serum, collected with precautions to keep the serum chilled, both the BsAb (Fig. 4) (Fig. 5) . Peak serum levels of free BsAb were achieved at the end of the infusion period in all patients, and ranged from 0.08 to 0.27 p,g/ml.
In the patients with the solid tumors, it was not possible to monitor the effects of BsAb on the tumor population. However, the function of the antibody was indicated by the fact that the circulating neutrophils decreased dramatically after each infusion. Despite this phenomenon, there were no associated signs or symptoms of acute reaction or of infection.
DISCUSSION
Redirected cellular cytotoxicity mediated by BsAb is a new form of immunotherapy with potential advantages over unmodified antibody therapy and other immunoconjugates such as immunotoxins. These advantages include a probable lack of toxicity, since no inherently toxic compounds would be introduced into the host, the use of normal in vivo cytotoxic mechanisms, and the ability to recruit very large numbers of cytotoxic cells to the target.
We are particularly interested in the role of mononuclear phagocytes in mediating cytotoxicity of tumor cells through FC7RI (CD64) (Anderson etal, 1986; Guyre et al, 1989) . Using bispecific antibodies comprised (Ball et al, 1983) , SCCL (Huang et al, 1983) , colorectal cancer (Brockhaus et al, 1982) , and breast carcinoma (Vredenburgh et al, 1991 (Ball etal, 1990 ). (Clark et al, 1991) . In the most promising and extensive series of studies to date, IL-2-activated lymphocytes and an anti-CD3 x anti-glioma BsAb were injected intracranially in 20 patients with malignant glioma (Nitta et al, 1990) . After 2 years, 76% of patients treated with BsAb and lymphocytes were tumor free, as compared with 33% of patients given IL-2-activated lymphocytes and no BsAb.
In summary, our results and those cited above indicate that BsAb may be most efficacious for high-risk tumors after induction of remission, after bone marrow transplant, and for treatment of minimal residual disease.
